PMID- 12663296
OWN - NLM
STAT- MEDLINE
DCOM- 20030424
LR  - 20180330
IS  - 0002-9165 (Print)
IS  - 0002-9165 (Linking)
VI  - 77
IP  - 4
DP  - 2003 Apr
TI  - Gamma-linolenic acid supplementation for prophylaxis of atopic dermatitis--a 
      randomized controlled trial in infants at high familial risk.
PG  - 943-51
AB  - BACKGROUND: Studies suggest that low concentrations of n-6 long-chain polyenes in 
      early life are correlated to atopic disease in later life. OBJECTIVE: The purpose 
      of the study was to investigate the possible preventive effect of gamma-linolenic 
      acid (GLA) supplementation on the development of atopic dermatitis in infants at 
      risk. DESIGN: In a double-blind, randomized, placebo-controlled trial, 
      formula-fed infants (n = 118) with a maternal history of atopic disease received 
      borage oil supplement (containing 100 mg GLA) or sunflower oil supplement as a 
      placebo daily for the first 6 mo of life. Main outcome measures were the 
      incidence of atopic dermatitis in the first year of life (by UK Working Party 
      criteria), the severity of atopic dermatitis (SCORing Atopic Dermatitis; SCORAD), 
      and the total serum immunoglobulin E (IgE) concentration at the age of 1 y. 
      RESULTS: The intention-to-treat analysis showed a favorable trend for severity of 
      atopic dermatitis associated with GLA supplementation ( x+/- SD SCORAD: 6.32 +/- 
      5.32) in the GLA-supplemented group as compared with 8.28 +/- 6.54 in the placebo 
      group (P = 0.09; P = 0.06 after adjustment for total serum IgE at baseline, age 1 
      wk), but no significant effects on the other atopic outcomes. The increase in GLA 
      concentrations in plasma phospholipids between baseline and 3 mo was negatively 
      associated with the severity of atopic dermatitis at 1 y (Spearman's correlation 
      coefficient = -0.233, P = 0.013). There was no significant effect on total serum 
      IgE concentration. CONCLUSION: Early supplementation with GLA in children at high 
      familial risk does not prevent the expression of atopy as reflected by total 
      serum IgE, but it tends to alleviate the severity of atopic dermatitis in later 
      infancy in these children.
FAU - van Gool, Christel J A W
AU  - van Gool CJ
AD  - Department of Epidemiology, Nutrition and Toxicology Research Institute, 
      Maastricht University, Maastricht, Netherlands. c.vangool@epid.unimaas.nl
FAU - Thijs, Carel
AU  - Thijs C
FAU - Henquet, Charles J M
AU  - Henquet CJ
FAU - van Houwelingen, Adriana C
AU  - van Houwelingen AC
FAU - Dagnelie, Pieter C
AU  - Dagnelie PC
FAU - Schrander, Jaap
AU  - Schrander J
FAU - Menheere, Paul P C A
AU  - Menheere PP
FAU - van den brandt, Piet A
AU  - van den brandt PA
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Nutr
JT  - The American journal of clinical nutrition
JID - 0376027
RN  - 0 (Placebos)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 78YC2MAX4O (gamma-Linolenic Acid)
SB  - IM
MH  - Dermatitis, Atopic/*prevention & control
MH  - Dietary Supplements
MH  - Double-Blind Method
MH  - Gestational Age
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Infant
MH  - Infant, Newborn
MH  - Mothers
MH  - Patient Compliance
MH  - Placebos
MH  - Risk Factors
MH  - Treatment Outcome
MH  - gamma-Linolenic Acid/*administration & dosage/blood
EDAT- 2003/03/29 05:00
MHDA- 2003/04/25 05:00
CRDT- 2003/03/29 05:00
PHST- 2003/03/29 05:00 [pubmed]
PHST- 2003/04/25 05:00 [medline]
PHST- 2003/03/29 05:00 [entrez]
AID - 10.1093/ajcn/77.4.943 [doi]
PST - ppublish
SO  - Am J Clin Nutr. 2003 Apr;77(4):943-51. doi: 10.1093/ajcn/77.4.943.